Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 118, Issue 8, pp 629–634 | Cite as

Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma

  • N. Neuhold
  • F. Längle
  • M. Gnant
  • U. Hollenstein
  • B. Niederle
Original Papers Clinical Oncology

Summary

Immunoreactivity with monoclonal antibody CD15 (Leu-M1) was investigated in the primary tumours, the metastases and local recurrences of 47 cases of sporadic medullary carcinoma of the thyroid (MTC). Of these tumours, 36.5% showed a varying degree of CD15 immunostaining; in 7 carcinomas the CD15 immunoreactivity was found to be significant (>15% tumour cells positively stained). Staining of the amyloid stroma was observed in 3 tumours. Significantly higher epithelial CD15 positivity was seen more frequently in the group with larger tumours (>4 cm) and was found exclusively in the presence of lymph node metastases. No substantial difference in the percentage of immunostained cells was seen between primary tumours and metastatic or recurrent lesions, except for two cases that revealed a significant increase in the number of CD15-immunostained cells in metastatic and recurrent lesions. Five of 7 patients with recurrences showing significant CD15 immunostaining died of cancer, while in the absence of significant CD15 staining all patients with recurrences were still alive at the conclusion of the study. The prognostic value of CD15 immunoreactivity, found by univariate analysis, becomes weaker after adjustment for the size and stage of tumour. Particularly in patients with tumour recurrences CD15 immunostaining may be of clinical relevance for the selection of patients in whom a more radical surgical approach would be justified.

Key words

Medullary thyroid carcinoma Prognosis Immunohistochemistry 

Abbreviations

MTC

medullary thyroid carcinoma

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Axiotis CA, Jennings TA (1988) Observations on bronchiolo-alveolar carcinoma with special emphasis on localized lesions. Am J Surg Pathol 12:918–931Google Scholar
  2. Bergholm U, Adami HO, Auer G, Bergström R, Bäckdahl M, Grimelius L, Hansson G, Ljungberg O, Wilander E, the Swedish MTC Study Group (1989) Histopathologic characteristics and nuclear DNA-content as prognostic factors in medullary thyroid carcinoma. Cancer 64:135–142Google Scholar
  3. Bergholm U, Adami HO, Bergström R, Bäckdahl M, Akerström G, the Swedish MTC Study Group (1990) Long term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. Acta Chir Scand 156:37–46Google Scholar
  4. Block MA, Jackson CE, Greenwald KA, Yott JB, Tashijan AH (1980) Clinical characteristics distinguishing hereditary from sporadic medullary carcinoma: treatment implications. Arch Surg 115:142–148Google Scholar
  5. Brunt LM, Wells SA Jr (1987) Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin N Am 67:263–278Google Scholar
  6. Chong GC, Beahrs OH, Sizemore GW, Woolner LH (1975) Medullary carcinoma of the thyroid gland. Cancer 35:695–704Google Scholar
  7. Fenlon S, Ellis IQ, Bell J, Todd JH, Elston CW, Blamey RW (1987)Helix pomatia andUlex europaeus lectin binding in human breast carcinoma. J Pathol 152:169–172Google Scholar
  8. Grauer A, Raue F, Gagel RF (1990) Changing concepts in the management of hereditary and sporadic medullary carcinoma. Endocrinol Metab Clin North Am 19:613–6335Google Scholar
  9. Hakomori SI, Kannagi R (1983) Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer Inst 71:231–251Google Scholar
  10. Hakomori S, Nudelman E, Kannagi R, Levery SB (1982) The common structure in fucosyllactosaminolipids accumulation in human adenocarcinomas, and its possible absence in normal tissue. Biochem Biophys Res Commun 109:36–44Google Scholar
  11. Hanjan SN, Kearney JF, Cooper MD (1982) A monoclonal antibody (MMA) that identifies a differentiation antigen on myelomonocytic cells. Clin Immunol Immunopathol 23:172–188Google Scholar
  12. Harrach HR, Wilander E, Grimelius L, Bergholm U, Westermark P, Falkmer S (1992) Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma. Pathol Res Pract 188:123–130Google Scholar
  13. Hermanek P, Sobin LH (eds) (1987) TNM classification of malignant tumors, 4th edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  14. Holm R, Sobrinho-Simoes M, Nesland JM, Gould VE, Johannessen JV (1985) Medullary carcinoma of the thyroid gland: an immunocytochemical study. Ultrastruct Pathol 8:25–41Google Scholar
  15. Hsu SM, Jaffe ES (1984) Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin disease. Am J Clin Pathol 82:29–32Google Scholar
  16. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedure. J Histochem Cytochem 29:577–580Google Scholar
  17. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. Am Stat Assoc J 53:457–481Google Scholar
  18. Kim YS, Kim YW, Siddiqui B, Tsao D (1982) Membrane-associated, fucose-containing glycoproteins and glycolipids of cultured epithelial cells from human colonic adenocarcinoma and fetal intestine. Eur J Cancer Clin Oncol 18:1329–1336Google Scholar
  19. Mantel N (1963) Chi-square test with one degree of freedom; extensions of the Mantel-Hanszel procedure. J Am Stat Assoc 58:690–700Google Scholar
  20. Mascarel I, Trojani M, Eghbali H, Coindre JM, Bonichon F (1990) Prognostic value of phenotyping by Ber-H2, Leu-M1, EMA in Hodgkin's disease. Arch Pathol Lab Med 114:953–955Google Scholar
  21. Mendelsohn G, Wells SA, Baylin SB (1984) Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. Cancer 54:657–662Google Scholar
  22. Parham DM, Morton K, Coghill G, Robertson AJ, Kerr MA (1990) Expression of CD15 antigen in urinary bladder transitional cell carcinoma. J Clin Pathol 43:541–543Google Scholar
  23. Petrella T, Michiels JF, Michiels R, Collin F, Nabholz JM, Friedman S, Fargeot P (1989) CD15 antigen in Hodgkin's disease. Path Res Pract 185:886–890Google Scholar
  24. Pinkus GS, Said JW (1986) Leu M1 immunoreactivity in non haematopoetic neoplasms and myeloproliferative disorders. An immunoperoxidase study of paraffin sections. Am J Clin Pathol 85:278–282Google Scholar
  25. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC, Samaan NA (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63:319–343Google Scholar
  26. Saad MF; Ordonez NG, Guido JJ, Samaan NA (1985) The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889–894Google Scholar
  27. Schröder S, Schwarz W, Rehpenning W, Dralle H, Bay V, Böcker W (1988a) Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid. J Cancer Res Clin Oncol 114:291–296Google Scholar
  28. Schröder S, Böcker W, Baisch H, Bürck CG, Arps H, Meiners I, Kastendieck H, Heitz PU, Klöppel G (1988b) Prognostic factors in medullary thyroid carcinomas: survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer 61:806–816Google Scholar
  29. Schröder S, Dralle H, Bay V, Böcker W (1989) Immunhistologie und Prognose beim Schilddrüsenkarzinom. Bestimmung des Malignitätspotentials papillärer und medullärer Neoplasien durch S-100 Protein und Leu M-1 Antigen Nachweis. AMA 1:2–5Google Scholar
  30. Sewell HF, Jaffray B, Thompson WD (1987) Reaction of monoclonal anti Leu-M1 — a myelomonocytic marker (CD-15) — with normal and neoplastic epithelia. J Pathol 151:279–284Google Scholar
  31. Sheibani K, Battifora H, Burke JS, Rappaport H (1986) Leu-M1 antigen in human neoplasms. An immunhistologic study of 400 cases. Am J Surg Pathol 10:227–236Google Scholar
  32. Sipple JH (1961) The association of phaeochromocytoma with carcinoma of the thyroid. Am J Med 31:163–166Google Scholar
  33. Tisell LER, Jansson S (1988) Recent results of reoperative surgery in medullary carcinoma of the thyroid. Wien Klin Wochenschr 100:347Google Scholar
  34. Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60–66Google Scholar
  35. Van de Kaa CA, Hol PR, Huber J, Linke RP, Kooiker CJ, Gruys E (1986) Diagnosis of the type of amyloid in paraffin embedded tissue sections using antisera against human and animal amyloid proteins. Virchows Arch [A] 408:649–664Google Scholar
  36. Van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long term course of patients with persistent hypercalcitoninaemia after apparent curative primary surgery of medullary thyroid carcinoma. Ann Surg 212:395–401Google Scholar
  37. Williams ED (1985) Pathology and prognosis in medullary carcinoma of the thyroid. In: Jaffiol C, Millhod G (eds) Thyroid cancer. Elsevier, Amsterdam, pp 81–84Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • N. Neuhold
    • 1
  • F. Längle
    • 2
  • M. Gnant
    • 2
  • U. Hollenstein
    • 3
  • B. Niederle
    • 2
  1. 1.Institute of Clinical Pathology, Department of Pathological AnatomyUniversity of Vienna, General HospitalViennaAustria
  2. 2.1st Department of SurgeryUniversity of Vienna, General HospitalViennaAustria
  3. 3.4th Clinic of Internal Medicine, Department of EndocrinologyUniversity of Vienna, General HospitalViennaAustria

Personalised recommendations